Gary Richmond

Broward Health Medical Center — United States

Medicine · Health Sciences

27h-index4.9kcitations59works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

HIV/AIDS drug development and treatment(37), HIV Research and Treatment(32), HIV/AIDS Research and Interventions(19), HIV-related health complications and treatments(7), Pneumocystis jirovecii pneumonia detection and treatment(7)

Publications55 total

1596. Efficacy and Safety of Long-Acting Subcutaneous Lenacapavir in Heavily Treatment-Experienced People with Multi-Drug Resistant HIV: Week 104 Results
Open Forum Infectious Diseases·2023· 6 citedOpen Access
Efficacy and safety of the novel capsid inhibitor lenacapavir to treat multidrug-resistant HIV: week 52 results of a phase 2/3 trial
The Lancet HIV·2023· 61 cited
Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority Study
Clinical Infectious Diseases·2023· 107 citedOpen Access
Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection
New England Journal of Medicine·2022· 270 citedOpen Access
Peirce on Abduction and Diagrams in Mathematical Reasoning
2022· 1 cited
Long-acting cabotegravir and rilpivirine for HIV-1 suppression: switch to 2-monthly dosing after 5 years of daily oral therapy
AIDS·2021· 34 citedOpen Access
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study
The Lancet HIV·2021· 131 cited
Efficacy, Safety, and Durability of Long-Acting Cabotegravir and Rilpivirine in Adults With HIV-1 Infection: ~5-Year Results From the LATTE-2 Study
Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona)·2021Open Access
Efficacy, Safety, and Durability of Long-Acting Cabotegravir and Rilpivirine in Adults With Human Immunodeficiency Virus Type 1 Infection: 5-Year Results From the LATTE-2 Study
Open Forum Infectious Diseases·2021· 58 citedOpen Access
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study
The Lancet·2020· 343 cited
Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study
UNC Libraries·2020· 1 citedOpen Access
116. Antiviral Activity and Safety of Long-acting Cabotegravir (CAB LA) Plus Long-acting Rilpivirine (RPV LA), Administered Every 2 Months (Q2M), in Hiv-positive Subjects: Results from the POLAR Study
Open Forum Infectious Diseases·2020· 1 citedOpen Access
Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials
JAIDS Journal of Acquired Immune Deficiency Syndromes·2020· 137 citedOpen Access
Intraspecific variation in thermal acclimation and tolerance between populations of the winter ant, <i>Prenolepis imparis</i>
Ecology and Evolution·2020· 24 citedOpen Access
Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression
New England Journal of Medicine·2020· 525 citedOpen Access
Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1
New England Journal of Medicine·2018· 220 citedOpen Access
Experiences with long acting injectable ART: A qualitative study among PLHIV participating in a Phase II study of cabotegravir + rilpivirine (LATTE-2) in the United States and Spain
PLoS ONE·2018· 163 citedOpen Access
Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial
The Lancet HIV·2017· 96 cited
Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial
The Lancet·2017· 493 cited
Forty-eight-Week Safety and Efficacy On-Treatment Analysis of Ibalizumab in Patients with Multi-Drug Resistant HIV-1
Open Forum Infectious Diseases·2017· 9 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

Edwin DeJesus(11), William Spreen(10), David A. Margolis(8), Kimberly Y. Smith(8), Moti Ramgopal(7), Susan L. Ford(6), Herta Crauwels(6), Rodica Van Solingen‐Ristea(6), Jean‐Michel Molina(6), Princy Kumar(6), Jacob Lalezari(6), Peter Ruane(6), Cynthia Brinson(6), Kati Vandermeulen(6), Jaime Andrade‐Villanueva(5), Giuliano Rizzardini(5), Simon Vanveggel(5), Yazdan Yazdanpanah(5), Kenneth Sutton(5), Susan Swindells(4)